Literature DB >> 24532105

Evaluation of Factor V G1691A, prothrombin G20210A, Factor XIII V34L, MTHFR A1298C, MTHFR C677T and PAI-1 4G/5G genotype frequencies of patients subjected to cardiovascular disease (CVD) panel in south-east region of Turkey.

Serdar Oztuzcu1, Sercan Ergun, Mustafa Ulaşlı, Gülper Nacarkahya, Yusuf Ziya Iğci, Mehri Iğci, Recep Bayraktar, Ali Tamer, Ecir Ali Çakmak, Ahmet Arslan.   

Abstract

Cardiovascular disease (CVD) risk factors, such as arterial hypertension, obesity, dyslipidemia or diabetes mellitus, as well as CVDs, including myocardial infarction, coronary artery disease or stroke, are the most prevalent diseases and account for the major causes of death worldwide. In the present study, 4,709 unrelated patients subjected to CVD panel in south-east part of Turkey between the years 2010 and 2013 were enrolled and DNA was isolated from the blood samples of these patients. Mutation analyses were conducted using the real-time polymerase chain reaction method to screen six common mutations (Factor V G1691A, PT G20210A, Factor XIII V34L, MTHFR A1298C and C677T and PAI-1 -675 4G/5G) found in CVD panel. The prevalence of these mutations were 0.57, 0.25, 2.61, 13.78, 9.34 and 24.27 % in homozygous form, respectively. Similarly, the mutation percent of them in heterozygous form were 7.43, 3.44, 24.91, 44.94, 41.09 and 45.66%, respectively. No mutation was detected in 92 (1.95%) patients in total. Because of the fact that this is the first study to screen six common mutations in CVD panel in south-east region of Turkey, it has a considerable value on the diagnosis and treatment of these diseases. Upon the results of the present and previous studied a careful examination for these genetic variants should be carried out in thrombophilia screening programs, particularly in Turkish population.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24532105     DOI: 10.1007/s11033-014-3231-5

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  37 in total

Review 1.  Advances in understanding pathogenic mechanisms of thrombophilic disorders.

Authors:  Björn Dahlbäck
Journal:  Blood       Date:  2008-07-01       Impact factor: 22.113

2.  Frequency of Factor V (1691 G --> A) mutation in Turkish population.

Authors:  N Akar; E Akar; G Dalgin; A Sözüöz; K Omürlü; S Cin
Journal:  Thromb Haemost       Date:  1997-12       Impact factor: 5.249

3.  The prothrombin gene G20210A variant: prevalence in a U.K. anticoagulant clinic population.

Authors:  A M Cumming; S Keeney; A Salden; M Bhavnani; K H Shwe; C R Hay
Journal:  Br J Haematol       Date:  1997-08       Impact factor: 6.998

4.  Examining thrombin hydrolysis of the factor XIII activation peptide segment leads to a proposal for explaining the cardioprotective effects observed with the factor XIII V34L mutation.

Authors:  T A Trumbo; M C Maurer
Journal:  J Biol Chem       Date:  2000-07-07       Impact factor: 5.157

5.  A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural-tube defects?

Authors:  N M van der Put; F Gabreëls; E M Stevens; J A Smeitink; F J Trijbels; T K Eskes; L P van den Heuvel; H J Blom
Journal:  Am J Hum Genet       Date:  1998-05       Impact factor: 11.025

6.  Frequency of genetic mutations associated with thromboembolism in the Western Black Sea Region.

Authors:  Esra Tug; Hatip Aydin; Ebru Kaplan; Dilek Dogruer
Journal:  Intern Med       Date:  2011-01-01       Impact factor: 1.271

7.  Genotype and allele frequencies of the polymorphic methylenetetrahydrofolate reductase gene in Turkey.

Authors:  Ali Sazci; Emel Ergul; Guner Kaya; Ihsan Kara
Journal:  Cell Biochem Funct       Date:  2005 Jan-Feb       Impact factor: 3.685

8.  The prevalence of factor V (G1691A), MTHFR (C677T) and PT (G20210A) gene mutations in arterial thrombosis.

Authors:  Füsun Ozmen; M Mahir Ozmen; Nejdet Ozalp; Nejat Akar
Journal:  Ulus Travma Acil Cerrahi Derg       Date:  2009-03

9.  Plasminogen activator inhibitor 1 4G/5G polymorphism and coagulation factor XIII Val34Leu polymorphism: impaired fibrinolysis and early pregnancy loss.

Authors:  Astrid Dossenbach-Glaninger; Michael van Trotsenburg; Martin Dossenbach; Christian Oberkanins; Anne Moritz; Walter Krugluger; Johannes Huber; Pierre Hopmeier
Journal:  Clin Chem       Date:  2003-07       Impact factor: 8.327

10.  Role of genetic changes in the progression of cardiovascular diseases.

Authors:  S A Sheweita; H Baghdadi; A R Allam
Journal:  Int J Biomed Sci       Date:  2011-12
View more
  3 in total

1.  Rivaroxaban attenuates thrombosis by targeting the NF-κB signaling pathway in a rat model of deep venous thrombus.

Authors:  Junhao Ma; Xinxi Li; Yang Wang; Zhenwei Yang; Jun Luo
Journal:  Int J Mol Med       Date:  2017-09-29       Impact factor: 4.101

Review 2.  Methylenetetrahydrofolate reductase and psychiatric diseases.

Authors:  Lin Wan; Yuhong Li; Zhengrong Zhang; Zuoli Sun; Yi He; Rena Li
Journal:  Transl Psychiatry       Date:  2018-11-05       Impact factor: 6.222

3.  Genetic risk factors in patients with deep venous thrombosis, a retrospective case control study on Iranian population.

Authors:  Soudabeh Hosseini; Ebrahim Kalantar; Maryam Sadat Hosseini; Shadi Tabibian; Morteza Shamsizadeh; Akbar Dorgalaleh
Journal:  Thromb J       Date:  2015-11-10
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.